Glass dominates the prefilled syringe (PFS) market, but the use of polymer is expected to grow in the next few years. Glass’s excellent barrier properties and regulatory ease make it the first choice for drug manufacturers, but polymer’s stability and inert properties, as well as its wide design options, mean it is an attractive choice as well. So drug manufacturers must ask themselves an important question: Is glass or polymer the better material for PFSs?
Each material has its strengths and weaknesses – there’s no outright winner in this debate. The question itself as to which is better can also be misguided. Before analysing the benefits and drawbacks of each material, pharmaceutical developers must take a holistic view of the drug and a patient’s needs to find what works best for a particular application.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.